Search

Your search keyword '"Westhovens, R."' showing total 1,121 results
Start Over Author "Westhovens, R."
1,121 results on '"Westhovens, R."'

154. Digital ulcers predict a worse disease course in patients with systemic sclerosis

Author

Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirják L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U1 Matucci-Cerinic M, Launay D, Dobrotă R, Sfrenţ-Cornăţeanu R, Zingarelli S, Pigatto E, Cuomo G, Caramaschi P, Ananieva L, Ullman S, Iversen L, Gurman AB, Braun-Moscovici Y, Carreira PE, Joven BE, Minier T, Guiducci S, Bellando-Randone S, Pellerito R, Hunzelmann N, Tarner IH, Radominski SC, de Souza Müller C, Iannone F, Henes J, Bancel DF, Damjanov N, Ostojić P, Pozzi MR, Hesselstrand R, Denton C, Krasowska D, Tikly M, Riccieri V, Cantatore FP, Corrado A, Da Silva JA, Salvador MJ, Tyndall A, Gabrielli A, Distler O, Jordan S, Heitmann S, Burkhardt H, Himsel A, Rozman B, Smith V, De Keyser F, Kalitena DM, Radic M, Filipescu I, Petcu A, Vlachoyiannopoulos P, Kucharz EJ, Widuchowska M, Kopec-Medrek M, Kotulska A, Szücs G, Stankovic A, Stamenkovic B, Selmi CF, De Santis M, Marasini B, Coleiro B, Santamaria VO, Westhovens R, Bečvář R, Novak S, Engelhart M, Meroni P, Ingegnoli F, Zeni S, Sulli A, Distler J, Yavuz S, Montecucco C, Eyerich K, Krummel-Lorenz B, Zenone T, Midtvedt Ø, Chizzolini C, Seidel M, Oleszowsky M, Üprus M, Opriş D, Groşeanu L, Bielecka OK, Antonio ZM, Szechinski J, Morović-Vergles J, Scorza R, Puppo F, Mathieu A, Anic B, Stork J, Stebbings S, Inanc M, Hasler P, von Mühlen CA, Aringer M, Popa S, Li M, Rosato E., Mihai, C, Landewé, R, van der Heijde, D, Walker, Ua, Constantin, Pi, Gherghe, Am, Ionescu, R, Rednic, S, Allanore, Y, Avouac, J, Czirják, L, Hachulla, E, Riemekasten, G, Cozzi, F, Airò, P, Cutolo, M, Mueller-Ladner U1 Matucci-Cerinic, M, Launay, D, Dobrotă, R, Sfrenţ-Cornăţeanu, R, Zingarelli, S, Pigatto, E, Cuomo, G, Caramaschi, P, Ananieva, L, Ullman, S, Iversen, L, Gurman, Ab, Braun-Moscovici, Y, Carreira, Pe, Joven, Be, Minier, T, Guiducci, S, Bellando-Randone, S, Pellerito, R, Hunzelmann, N, Tarner, Ih, Radominski, Sc, de Souza Müller, C, Iannone, F, Henes, J, Bancel, Df, Damjanov, N, Ostojić, P, Pozzi, Mr, Hesselstrand, R, Denton, C, Krasowska, D, Tikly, M, Riccieri, V, Cantatore, Fp, Corrado, A, Da Silva, Ja, Salvador, Mj, Tyndall, A, Gabrielli, A, Distler, O, Jordan, S, Heitmann, S, Burkhardt, H, Himsel, A, Rozman, B, Smith, V, De Keyser, F, Kalitena, Dm, Radic, M, Filipescu, I, Petcu, A, Vlachoyiannopoulos, P, Kucharz, Ej, Widuchowska, M, Kopec-Medrek, M, Kotulska, A, Szücs, G, Stankovic, A, Stamenkovic, B, Selmi, Cf, De Santis, M, Marasini, B, Coleiro, B, Santamaria, Vo, Westhovens, R, Bečvář, R, Novak, S, Engelhart, M, Meroni, P, Ingegnoli, F, Zeni, S, Sulli, A, Distler, J, Yavuz, S, Montecucco, C, Eyerich, K, Krummel-Lorenz, B, Zenone, T, Midtvedt, Ø, Chizzolini, C, Seidel, M, Oleszowsky, M, Üprus, M, Opriş, D, Groşeanu, L, Bielecka, Ok, Antonio, Zm, Szechinski, J, Morović-Vergles, J, Scorza, R, Puppo, F, Mathieu, A, Anic, B, Stork, J, Stebbings, S, Inanc, M, Hasler, P, von Mühlen, Ca, Aringer, M, Popa, S, Li, M, and Rosato, E.

Subjects
Epidemiology, Cardiovascular Disease, Systemic Sclerosis
Published
2016

157. DUTCH NORM SCORES FOR FOUR DUTCH-FLEMISH PROMIS ITEM BANKS IMPORTANT FOR PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Crins, M. H., Roorda, L. D., de Vet, H. C., Westhovens, R., Boers, M., Dekker, J., Terwee, C. B., Epidemiology and Data Science, APH - Methodology, AII - Inflammatory diseases, Rehabilitation medicine, CCA - Cancer Treatment and quality of life, Medical psychology, APH - Health Behaviors & Chronic Diseases, APH - Mental Health, CCA - Cancer biology and immunology, and APH - Aging & Later Life

Published
2017

158. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Author

Clowse, Megan E. B, Wallace, Daniel J., Furie, Richard A., Petri, Michelle A., Pike, Marilyn C., Leszczyński, Piotr, Neuwelt, C. Michael, Hobbs, Kathryn, Keiserman, Mauro, Duca, Liliana, Kalunian, Kenneth C., Galateanu, Catrinel, Bongardt, Sabine, Stach, Christian, Beaudot, Carolyn, Kilgallen, Brian, Gordon, Caroline, Batalov, A., Bojinca, M., Djerassi, R., Duca, L., Horak, P., Kolarov, Z., Milasiene, R., Monova, D., Otsa, K., Pileckyte, M., Popova, T., Radulescu, F., Rashkov, R., Rednic, S., Repin, M., Stoilov, R., Tegzova, D., Vezikova, N., Vitek, P., Zainea, C., East, Far, Baek, H., Chen, Y., Chiu, Y., Cho, C., Chou, C., Choe, J., Huang, C., Kang, Y., Kang, S., Lai, N., Lee, S., Park, W., Shim, S., Suh, C., Yoo, W., Armengol, H. Avila, Zapata, F. Avila, Santiago, M. Barreto, Cavalcanti, F., Chahade, W., Costallat, L., Keiserman, M., Alcala, J. Orozco, Remus, C. Ramos, Roimicher, L., Abu Shakra, M., Agarwal, V., Agmon Levin, N., Kadel, J., Levy, Y., Mevorach, D., Paran, D., Reitblat, T., Rosner, I., Shobha, V., Sthoeger, Z., Zisman, D., Ayesu, K., Berney, S., Box, J., Busch, H., Buyon, J., Carter, J., Chi, J., Clowse, M., Collins, R., Dao, K., Diab, I., Dikranian, A., El Shahawy, M., Gaylis, N., Grossman, J., Halpert, E., Huff, J., Jarjour, W., Kao, A., Katz, R., Kennedy, A., Khan, M., Kivitz, A., Kohen, M., Lawrence Ford, T., Lawson, J., Levesque, M., Lowenstein, M., Majjhoo, A., Mcarthur, R., Mclain, D., Merrill, J., Murillo, A., Neucks, S., Niemer, G., Noaiseh, G., Parker, C., Pantojas, C., Pattanaik, D., Petri, M., Pickrell, P., Reveille, J., Roman Miranda, A., Rothfield, N., Sankoorikal, A., Sayers, M., Singhal, A., Snyder, A., Striebich, C., Vo, Q., von Feldt, J., Wallace, D., Wasko, M., Young, C., Adelstein, S., Hall, S., Littlejohn, G., Nicholls, D., Suranyi, M., Amoura, Z., Bannert, B., Behrens, F., Perez, L. Carreno, Chakravarty, K., Gonzales, F. Diaz, Davies, K., Doria, Andrea, Emery, P., Fernández Nebro, A., Govoni, M., Hachulla, E., Hellmich, B., Houssiau, F., Malaise, M., Margaux, J., Maugars, Y., Muñoz Fernández, S., Navarro, F., Ordi Ros, J., Pellerito, R., Pena Sagredo, J., Roussou, E., Schmidt, R. E., Ucar Angulo, E., Viallard, J. F., Westhovens, R., Worm, M., Yee, C. S., Nayiager, S., Reuter, H., Spargo, C., Bazela, B., Brzosko, M., Chudzik, D., Gasztonyi, B., Geher, P., Ionescu, R., Jeka, S., Kemeny, L., Kiss, E., Kotyla, P., Kovacs, L., Kovalenko, V., Kucharz, E., Kwiatkowska, B., Leszczynski, P., Levchenko, E., Lysenko, G., Majdan, M., Mihailov, C., Nalotov, S., Nedelciu, M., Pavel, M., Raskina, T., Rebrov, B., Rezus, E., Semen, T., Smakotina, S., Stanislavchuk, M., Stanislav, M., Szombati, I., Szucs, G., Udrea, G., Zajdel, J., Zon Giebel, A., Bonfiglioli, R., Bustamante, R., Klumb, E., Ramirez, G. Medrano, Neiva, C., Olguin, M., Gonzaga, J. Reyes, Scotton, A., Ayala, S. Sicsik, Ximenes, A., Sharma, R., Srikantiah, C., Aelion, J., Aranow, C., Baker, M., Chadha, A., Chao, J., Chatham, W., Chow, A., Clay, C., Cohen Gadol, S., Conaway, D., Denburg, J., Escalante, A., Espinoza, L., Fiechtner, J., Fortin, I., Fraser, A., Furie, R., Gladman, D., Goddard, D., Goldberg, M., Gonzalez Rivera, R., Gorman, J., Griffin, R., Haaland, D., Halter, D., Hemaiden, A., Hobbs, K., Joshi, V., Lim, S., Kalunian, K., Karpouzas, G., Khraishi, M., Lafyatis, R., Lidman, R., Lue, C., Mohan, M., Mease, P., Mehta, C., Mizutani, W., Nami, A., Nascimento, J., Neuwelt, C., Pappas, J., Pope, J., Porges, A., Roane, G., Rosenberg, D., Ross, S., Saadeh, C., Scoville, C., Sherrer, Y., Solomon, M., Surbeck, W., Valenzuela, G., Waller, P., Alten, R., Baerwald, C., Bienvenu, B., Bombardieri, S., Braun, J., Dival, L., Espinosa, G., Fernandez, I. Figueroa, Gomez Reino, J., Gordon, C., Hiepe, F., Hopkinson, N., Isenberg, D., Jacobi, A., Jorgensen, C., Guern, V. Le, Paul, C., Pego Reigosa, J. M., Heredia, J. Rodriguez, Rubbert Roth, A., Sabbadini, M., Schroeder, J., Schwarting, A., Spieler, W., Valesini, G., Wollenhaupt, J., Mendoza, A. Zea, and Zouboulis, C.

Subjects
humanized, adult, rheumatology, monoclonal, antibodies, monoclonal, humanized, double-blind method, female, humans, lupus erythematosus, systemic, male, severity of illness index, treatment outcome, immunology and allergy, immunology, systemic, Antibodies, Monoclonal, Humanized, Systemic Lupus Erythematosus, NO, Immunology and Allergy, Rheumatology, Immunology, Lupus Erythematosus, Systemic, antibodies, lupus erythematosus
Abstract

Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double‐blind, placebo‐controlled trials, the EMBODY 1 and EMBODY 2 trials, assessing the efficacy and safety of epratuzumab in patients with moderately to severely active systemic lupus erythematosus (SLE). Methods Patients met ≥4 of the American College of Rheumatology revised classification criteria for SLE, were positive for antinuclear antibodies and/or anti–double‐stranded DNA antibodies, had an SLE Disease Activity Index 2000 (SLEDAI‐2K) score of ≥6 (increased disease activity), had British Isles Lupus Assessment Group 2004 index (BILAG‐2004) scores of grade A (severe disease activity) in ≥1 body system or grade B (moderate disease activity) in ≥2 body systems (in the mucocutaneous, musculoskeletal, or cardiorespiratory domains), and were receiving standard therapy, including mandatory treatment with corticosteroids (5–60 mg/day). BILAG‐2004 grade A scores in the renal and central nervous system domains were excluded. Patients were randomized 1:1:1 to receive either placebo, epratuzumab 600 mg every week, or epratuzumab 1,200 mg every other week, with infusions delivered for the first 4 weeks of each 12‐week dosing cycle, for 4 cycles. Patients across all 3 treatment groups also continued with their standard therapy. The primary end point was the response rate at week 48 according to the BILAG‐based Combined Lupus Assessment (BICLA) definition, requiring improvement in the BILAG‐2004 score, no worsening in the BILAG‐2004 score, SLEDAI‐2K score, or physician's global assessment of disease activity, and no disallowed changes in concomitant medications. Patients who discontinued the study medication were classified as nonresponders. Results In the EMBODY 1 and EMBODY 2 trials of epratuzumab, 793 patients and 791 patients, respectively, were randomized, 786 (99.1%) and 788 (99.6%), respectively, received study medication, and 528 (66.6%) and 533 (67.4%), respectively, completed the study. There was no statistically significant difference in the primary end point between the groups, with the week 48 BICLA response rates being similar between the epratuzumab groups and the placebo group (response rates ranging from 33.5% to 39.8%). No new safety signals were identified. Conclusion In patients with moderate or severely active SLE, treatment with epratuzumab + standard therapy did not result in improvements in response rates over that observed in the placebo + standard therapy group.

Published
2017

162. THU0191 Novel formulation of ct-p13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase i/iii randomised controlled trial

Author

Westhovens, R., primary, Yoo, D.H., additional, Jaworski, J., additional, Matyska-Piekarska, E., additional, Smiyan, S., additional, Ivanova, D., additional, Zielinska, A., additional, Raussi, E.-K., additional, Batalov, A., additional, Lee, S.J., additional, Lee, S.Y., additional, and Suh, J.H., additional

Published
2018
Full Text
View/download PDF

164. SAT0200 Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study

Author

Westhovens, R., primary, Alten, R., additional, Winthrop, K., additional, Greenwald, M., additional, Ponce, L., additional, Enriquez-Sosa, F., additional, Stanislavchuk, M., additional, Mazur, M., additional, Spindler, A., additional, Cseuz, R., additional, Nikulenkova, N., additional, Glowacka-Kulesz, M., additional, Szombati, I., additional, Dudek, A., additional, Mozaffarian, N., additional, Greer, J., additional, Kunder, R., additional, An, D., additional, Harrison, P., additional, Van der Aa, A., additional, Kavanaugh, A., additional, and Genovese, M., additional

Published
2018
Full Text
View/download PDF

173. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Author

Smolen, J.S., Landewe, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., Vollenhoven, R. van, Aletaha, D., Aringer, M., Boers, M, Buckley, C.D., Buttgereit, F., Bykerk, V., Cardiel, M., Combe, B., Cutolo, M., Eijk-Hustings, Y. van, Emery, P., Finckh, A., Gabay, C., Gomez-Reino, J., Gossec, L., Gottenberg, J.-E., Hazes, J.M., Huizinga, T., Jani, M., Karateev, D., Kouloumas, M., Kvien, T., Li, Z., Mariette, X., McInnes, I., Mysler, E., Nash, P., Pavelka, K., Poor, G., Richez, C., Riel, P. van, Rubbert-Roth, A., Saag, K., Silva, J., Stamm, T., Takeuchi, T., Westhovens, R., Wit, M. de, Heijde, D. van der, Smolen, J.S., Landewe, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., Vollenhoven, R. van, Aletaha, D., Aringer, M., Boers, M, Buckley, C.D., Buttgereit, F., Bykerk, V., Cardiel, M., Combe, B., Cutolo, M., Eijk-Hustings, Y. van, Emery, P., Finckh, A., Gabay, C., Gomez-Reino, J., Gossec, L., Gottenberg, J.-E., Hazes, J.M., Huizinga, T., Jani, M., Karateev, D., Kouloumas, M., Kvien, T., Li, Z., Mariette, X., McInnes, I., Mysler, E., Nash, P., Pavelka, K., Poor, G., Richez, C., Riel, P. van, Rubbert-Roth, A., Saag, K., Silva, J., Stamm, T., Takeuchi, T., Westhovens, R., Wit, M. de, and Heijde, D. van der

Abstract

Contains fulltext : 177336.pdf (publisher's version ) (Closed access)

Published
2017

174. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Author

Smolen, J.S. (Josef S.), Landewé, R.B.M. (Robert), Bijlsma, J.W.J. (Hans), Burmester, G.R. (Gerd), Chatzidionysiou, K. (Katerina), Dougados, M. (Maxime), Nam, N. (Nguyen) van, Ramiro, S. (Sofia), Voshaar, M. (Marieke), Van Vollenhoven, R.F. (Ronald F.), Aletaha, D. (Daniel), Aringer, M. (Martin), Boers, M. (Maarten), Buckley, C.D., Buttgereit, F. (Frank), Bykerk, V.P. (Vivian), Cardiel, M. (Mario), Combe, B. (Bernard), Cutolo, M. (Maurizio), Van Eijk-Hustings, Y. (Yvonne), Emery, P. (Paul), Finckh, A. (Axel), Gabay, C. (Cem), Gómez-Reino, J.J. (Juan), Gossec, L. (Laure), Gottenberg, J.-E. (Jacques-Eric), Hazes, J.M.W. (Mieke), Huizinga, T.W.J. (Tom), Jani, M. (Meghna), Karateev, D. (Dmitry), Kouloumas, M. (Marios), Kvien, T.K. (Tore), Li, Z. (Zhanguo), Mariette, X. (Xavier), McInnes, I.B. (Iain), Mysler, E. (Eduardo), Nash, P. (Peter), Pavelka, K. (Karel), Poor, R.A. (Raymond), Richez, C. (Christophe), Riel, P.L.C.M. (Piet) van, Rubbert-Roth, A. (Andrea), Saag, K.G. (Kenneth), Da Silva, J. (Jose), Stamm, T. (Tanja), Takeuchi, T. (Tsutomu), Westhovens, R. (René), M. de Wit (Maarten), Van Der Heijde, D. (Désirée), Smolen, J.S. (Josef S.), Landewé, R.B.M. (Robert), Bijlsma, J.W.J. (Hans), Burmester, G.R. (Gerd), Chatzidionysiou, K. (Katerina), Dougados, M. (Maxime), Nam, N. (Nguyen) van, Ramiro, S. (Sofia), Voshaar, M. (Marieke), Van Vollenhoven, R.F. (Ronald F.), Aletaha, D. (Daniel), Aringer, M. (Martin), Boers, M. (Maarten), Buckley, C.D., Buttgereit, F. (Frank), Bykerk, V.P. (Vivian), Cardiel, M. (Mario), Combe, B. (Bernard), Cutolo, M. (Maurizio), Van Eijk-Hustings, Y. (Yvonne), Emery, P. (Paul), Finckh, A. (Axel), Gabay, C. (Cem), Gómez-Reino, J.J. (Juan), Gossec, L. (Laure), Gottenberg, J.-E. (Jacques-Eric), Hazes, J.M.W. (Mieke), Huizinga, T.W.J. (Tom), Jani, M. (Meghna), Karateev, D. (Dmitry), Kouloumas, M. (Marios), Kvien, T.K. (Tore), Li, Z. (Zhanguo), Mariette, X. (Xavier), McInnes, I.B. (Iain), Mysler, E. (Eduardo), Nash, P. (Peter), Pavelka, K. (Karel), Poor, R.A. (Raymond), Richez, C. (Christophe), Riel, P.L.C.M. (Piet) van, Rubbert-Roth, A. (Andrea), Saag, K.G. (Kenneth), Da Silva, J. (Jose), Stamm, T. (Tanja), Takeuchi, T. (Tsutomu), Westhovens, R. (René), M. de Wit (Maarten), and Van Der Heijde, D. (Désirée)

Abstract

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatolog

Published
2017
Full Text
View/download PDF

179. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis

Author

Tamirou, F. D'Cruz, D. Sangle, S. Remy, P. Vasconcelos, C. Fiehn, C. Del Mar Ayala Guttierez, M. Gilboe, I.-M. Tektonidou, M. Blockmans, D. Ravelingien, I. Le Guern, V. Depresseux, G. Guillevin, L. Cervera, R. Houssiau, F.A. Abramowicz, D. Atzeni, F. Danieli, M.G. De Clercq, L. De Ramon Garrido, E. De Keyser, F. Delahousse, M. Espinosa, G. Golstein, M. Hirsch, M. Karras, A. Lang, P. Marchal, M. Marinho, A. Max, R. Peeters, P. Petera, P. Petrovic, R. Quémeneur, T. Raeman, F. Sarzi-Puttini, P. De Santis, L.V. Verresen, L. Weiss, L. Westhovens, R. MAINTAIN Nephritis Trial Group

Subjects
urologic and male genital diseases
Abstract

Objective: To report the 10-year follow-up of the MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy of proliferative lupus nephritis, and to test different definitions of early response as predictors of long-term renal outcome. Methods: In 2014, data on survival, kidney function, 24 h proteinuria, renal flares and other outcomes were collected for the 105 patients randomised between 2002 and 2006, except in 13 lost to follow-up. Results: Death (2 and 3 in the AZA and MMF groups, respectively) and end-stage renal disease (1 and 3, respectively) were rare events. Time to renal flare (22 and 19 flares in AZA and MMF groups, respectively) did not differ between AZA and MMF patients. Patients with good long-term renal outcome had a much more stringent early decrease of 24 h proteinuria compared with patients with poor outcome. The positive predictive value of a 24 h proteinuria

Published
2016

180. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial

Author

Stoenoiu, Maria S, Aydin, Selda, Tektonidou, Maria, Ravelingien, Isabelle, le Guern, Véronique, Fiehn, Christoph, Remy, Philippe, Delahousse, Michel, Petera, Peter, Quémeneur, Thomas, Vasconcelos, Carlos, D'Cruz, David, Gilboe, Inge-Magrethe, Jadoul, Michel, Karras, Alexandre, Depresseux, Geneviève, Guillevin, Loïc, Cervera, Ricard, Cosyns, Jean-Pierre, Houssiau, Frédéric A, Abramowicz, D, Atzeni, F, Blockmans, D, Danieli, Mg, de Keyser, F, Espinosa, G, Golstein, M, Hirsch, M, Lang, P, Marchal, M, Marinho, A, Max, R, Peeters, P, Petrovic, R, Raeman, F, Sarzi-Puttini, P, Sangle, S, Solé, M, de Santis LV, Verresen, L, Weiss, L, and Westhovens, R.

Subjects
Adult, Male, Nephrology, medicine.medical_specialty, Adolescent, Biopsy, Lupus nephritis, Pain, Azathioprine, Kidney, Gastroenterology, Mycophenolic acid, Young Adult, renal biopsy, Maintenance therapy, Internal medicine, medicine, Humans, Transplantation, medicine.diagnostic_test, azathioprine, lupus nephritis, mycophenolate mofetil, pathology, Female, Follow-Up Studies, Immunosuppressive Agents, Incidence, Lupus Nephritis, Middle Aged, Mycophenolic Acid, Treatment Outcome, business.industry, medicine.disease, Surgery, Renal biopsy, business, Nephritis, medicine.drug
Abstract

BACKGROUND: In the MAINTAIN Nephritis Trial, azathioprine (AZA) and mycophenolate mofetil (MMF) were compared as maintenance immunosuppressive treatment of proliferative lupus nephritis (LN) after a short-course of intravenous cyclophosphamide. Here, we compare the pathological findings on repeat kidney biopsies between the two groups. METHODS: Per protocol, repeat renal biopsies were obtained in 30 patients (16 AZA and 14 MMF) at 2 years (±6 months). Baseline and follow-up biopsies were graded according to the International Society of Nephrology/Renal Pathological Society (ISN/RPS) classification. The activity and chronicity indices (AI, CI) were calculated using two different semiquantitative scoring systems (Morel-Maroger and National Institutes of Health). Statistics were performed by non-parametric tests. RESULTS: The clinical characteristics of the 30 re-biopsied patients only marginally differ from the entire MAINTAIN cohort (105 patients). Clinical baseline and follow-up characteristics of AZA- and MMF-treated re-biopsied patients did not differ. Time (SD) to repeat renal biopsy was 25.0 (2.0) and 26.5 (3.3) months in AZA and MMF patients, respectively. More patients had normal renal biopsies or Classes I/II/V LN at follow-up compared to baseline and conversely, less patients had Class IV LN at follow-up. In both groups, the AI statistically decreased at follow-up compared to baseline, while the CI slightly, but significantly, increased. No differences could be detected between the groups. CONCLUSION: Centralized pathological analyses, including ISN/RPS classification and comparisons of AI/CI, failed to find differences between MMF and AZA at 2 years, a result well in line with the absence of difference in long-term clinical outcome reported elsewhere.

Published
2011

182. FRI0219 Association between conversion to ACPA/RF seronegative status and clinical outcomes following treatment with abatacept in combination with methotrexate compared with methotrexate alone in patients with early rheumatoid arthritis and poor prognostic indicators

Author

Jansen, D, primary, Emery, P, additional, Smolen, J, additional, Westhovens, R, additional, Bars, M Le, additional, Connolly, S, additional, Ye, J, additional, Toes, R, additional, and Huizinga, T, additional

Published
2017
Full Text
View/download PDF

183. THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks

Author

Alten, R, primary, Westhovens, R, additional, Kavanaugh, A, additional, Genovese, M, additional, Winthrop, K, additional, Greenwald, M, additional, Ponce, L, additional, Enriquez, F, additional, Stanislavchuk, M, additional, Mazur, M, additional, Spindler, A, additional, Cseuz, R, additional, Nikulenkova, N, additional, Glowacka-Kulesz, M, additional, Szombati, I, additional, Dudek, A, additional, Meuleners, L, additional, Tasset, C, additional, Harrison, P, additional, and Aa, A Van der, additional

Published
2017
Full Text
View/download PDF

185. THU0757-HPR European qualitative research project on patient-preferred outcomes in early rheumatoid arthritis (EQPERA): rationale, design and methods of an ongoing multi-country, multi-center, multi-language, longitudinal qualitative study

Author

Elst, K Van der, primary, Bremander, A, additional, Groef, A De, additional, Larsson, I, additional, Mathijssen, E, additional, Vriezekolk, J, additional, Westhovens, R, additional, and van Eijk-Hustings, Y, additional

Published
2017
Full Text
View/download PDF

191. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

Author

Westhovens, R, primary, Taylor, P C, additional, Alten, R, additional, Pavlova, D, additional, Enríquez-Sosa, F, additional, Mazur, M, additional, Greenwald, M, additional, Van der Aa, A, additional, Vanhoutte, F, additional, Tasset, C, additional, and Harrison, P, additional

Published
2016
Full Text
View/download PDF

192. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Author

Verschueren, P., de Cock, D., Corluy, L., Joos, R., Langenaken, C., Taelman, V., Raeman, F., Ravelingien, I., Vandevyvere, K., Lenaerts, J., Geens, E., Geusens, P., Vanhoof, J., Durnez, A., Remans, J., vander Cruyssen, B., van Essche, E., Sileghem, A., de Brabanter, G., Joly, J., van der Elst, K., Meyfroidt, S., Westhovens, R., CareRA study group, the, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Interne Geneeskunde, Public Health Sciences, and Cell Biology and Histology

Subjects
Glucocorticoids/therapeutic use, Male, Time Factors, Arthritis, Antirheumatic Agents/therapeutic use, Cobra, Severity of Illness Index, THERAPY, law.invention, Arthritis, Rheumatoid, Randomized controlled trial, Prednisone, law, Immunology and Allergy, Prospective Studies, skin and connective tissue diseases, Prospective cohort study, computer.programming_language, biology, Middle Aged, Prognosis, EULAR RECOMMENDATIONS, C-Reactive Protein, Treatment Outcome, Antirheumatic Agents, Area Under Curve, Female, Research Article, medicine.drug, Adult, musculoskeletal diseases, medicine.medical_specialty, Methotrexate/therapeutic use, Arthritis, Rheumatoid/blood, Immunology, AMERICAN-COLLEGE, Drug Administration Schedule, CLASSIFICATION, C-Reactive Protein/analysis, Rheumatology, Internal medicine, MANAGEMENT, medicine, Humans, Rheumatoid factor, Glucocorticoids, Aged, COMBINATION-TREATMENT STRATEGIES, Dose-Response Relationship, Drug, business.industry, TIGHT CONTROL, C-reactive protein, REMISSION, medicine.disease, Methotrexate, MODIFYING ANTIRHEUMATIC DRUGS, biology.protein, Physical therapy, FOLLOW-UP, business, computer, Biomarkers/blood, Biomarkers
Abstract

Introduction Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. Methods Disease-modifying antirheumatic drug–naïve patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti–citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP)) ≤3.2). Patients were randomized to 15 mg of MTX weekly (MTX with tight step-up (MTX-TSU)) or 15 mg of MTX weekly with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6 (COmbinatie therapie bij Reumatoïde Artritis (COBRA Slim)). A TSU approach was applied. Outcomes assessed were DAS28(CRP)-determined remission, cumulative disease activity, Health Assessment Questionnaire (HAQ) scores and adverse events (AEs) after 16 treatment weeks. Results We analyzed 43 COBRA Slim and 47 MTX-TSU patients and found that 65.1% in the COBRA Slim group and 46.8% in the MTX-TSU group reached remission (P = 0.081). Mean ± standard deviation area under the curve values of DAS28(CRP) were 13.84 ± 4.58 and 11.18 ± 4.25 for the MTX-TSU and COBRA Slim patients, respectively (P = 0.006). More COBRA Slim patients had an HAQ score of 0 (51.2% versus 23.4%, P = 0.006) at week 16. Therapy-related AEs between groups did not differ. Conclusion In patients with low-risk eRA, MTX with step-down glucocorticoid bridging seems more efficacious than MTX step-up monotherapy, with a comparable number of AEs observed over the first 16 treatment weeks. Trial registration EU Clinical Trials Register Identifier: EudraCT number 2008-007225-39. Registered 5 November 2008. Electronic supplementary material The online version of this article (doi:10.1186/s13075-015-0611-8) contains supplementary material, which is available to authorized users.

Published
2015

193. A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial

Author

Tamirou, F. Lauwerys, B.R. Dall'Era, M. Mackay, M. Rovin, B. Cervera, R. Houssiau, F.A. Abramowicz, D. Atzeni, F. Blockmans, D. Danieli, M.G. De Clercq, L. D'Cruz, D. Del Mar Ayala Guttierez, M. De Ramon Garrido, E. Gilboe, I.-M. De Keyser, F. Delahousse, M. Espinosa, G. Fiehn, C. Golstein, M. Guillevin, L. Hirsch, M. Karras, A. Lang, P. Le Guern, V. Marchal, M. Marinho, A. Max, R. Peeters, P. Petera, P. Petrovic, R. Quémeneur, T. Raeman, F. Remy, P. Ravelingien, I. Sarzi-Puttini, P. Sangle, S. Tektonidou, M. De Santis, L.V. Vasconcelos, C. Verresen, L. Weiss, L. Westhovens, R. MAINTAIN Nephritis Trial investigators

Abstract

Background: Although an early decrease in proteinuria has been correlated with good long-term renal outcome in lupus nephritis (LN), studies aimed at defining a cut-off proteinuria value are missing, except a recent analysis performed on patients randomised in the Euro-Lupus Nephritis Trial, demonstrating that a target value of 0.8 g/day at month 12 optimised sensitivity and specificity for the prediction of good renal outcome. The objective of the current work is to validate this target in another LN study, namely the MAINTAIN Nephritis Trial (MNT). Methods: Long-term (at least 7 years) renal function data were available for 90 patients randomised in the MNT. Receiver operating characteristic curves were built to test the performance of proteinuria measured within the 1st year as short-term predictor of long-term renal outcome. We calculated the positive and negative predictive values (PPV, NPV). Results: After 12 months of treatment, achievement of a proteinuria

Published
2015

194. Relationship between SNPs and Expression Level for Candidate Genes in Rheumatoid Arthritis

Author

Fodil, M., Teixeira, V. H., Chaudru, V., Hilliquin, P., Bombardieri, S., Balsa, A., Westhovens, R., Barrera, P., Alves, H., Migliorin, P., Bardin, T., Cornelis, F., Boudjema, A., Petit-Teixeira, Elisabeth, Migliorini, P., Dequeker, J., Pascuale-Salcedo, D., Van De Putte, L., Van Riel, P., Radstake, T. R., Lopes-Vaz, A., Fernandes, M., Vaz, C., Laboratoire de recherche européen pour la polyarthrite rhumatoïde (GenHotel), Université d'Évry-Val-d'Essonne (UEVE), Université des sciences et de la Technologie d'Oran Mohamed Boudiaf [Oran] (USTO MB), University College de Londres [U.K.] (UCL - U.K.), Centre Hospitalier Sud Francilien, CH Evry-Corbeil, Université de Pise, Service de Rhumatologie [CHU Lariboisière], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), La Paz Hospital, IdiPAZ, Center for Research in Ceramic and Composite Materials (CICECO), Universidade de Aveiro, and University of Pisa - Università di Pisa

Subjects
Adult, Genetic Markers, Male, Candidate gene, Genotype, Population, Immunology, Lymphocyte Antigen 96, Single-nucleotide polymorphism, Genome-wide association study, Eosinophil-Derived Neurotoxin, Biology, Polymorphism, Single Nucleotide, Arthritis, Rheumatoid, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Rheumatology, Immunology and Allergy, Humans, Calgranulin A, Genetic Predisposition to Disease, education, 030304 developmental biology, Genetic association, 030203 arthritis & rheumatology, Genetics, Medicine(all), 0303 health sciences, education.field_of_study, General Medicine, Middle Aged, 3. Good health, Interleukin-2 Receptor beta Subunit, Core Binding Factor Alpha 3 Subunit, IL2RB, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Genetic marker, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Cytokines, Female, Transcriptome
Abstract

International audience; Objectives: The study of polymorphisms of genes differentially expressed may lead to the identification of putative causal genetic variants in multifactorial diseases such as rheumatoid arthritis (RA). Based on preceding transcriptomic results, we genotyped 10 single nucleotide polymorphisms (SNPs) belonging to six genes (S100A8, RNASE2, PGLYRP1, RUNX3, IL2RB, and LY96) showing the highest fold change (\backslashtextgreater 1.9) when level of expression was compared between RA patients and controls. These SNPs were then analysed to evaluate their role in RA. Method: The relationship between gene expression and genotypes of SNPs was first investigated by Kruskal-Wallis and Mann-Whitney tests in RA patients and controls. The genetic association of these SNPs with RA were then analysed using family-based association tests in trio families. Results: We found that RNASE2 gene expression was related to rs2013109 genotypes in 14 RA patients (p = 0.030). The association study in a discovery sample of 200 French trio families revealed a significant association with RA for one SNP, PGLYRP1-rs2041992 (p = 0.019); this association was stronger in trios where RA patients carried the HLA-DRB1 shared epitope (SE) (p = 0.003). However, this association was not found in a replication sample of 240 European trio families (p = 0.6). Conclusions: Family-based association tests did not reveal an association between RA and any SNP of the candidate genes tested. However, RNASE2 gene expression was differentially expressed in RA patients considering a sequence polymorphism. This result led us to highlight the potential disease-specific regulation for this candidate gene in RA. © 2015 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation.

Published
2015

197. Het 'remitting seronegative symmetrical synovitis with pitting edema'(RS3PE)-syndroom

Author

null VAN LEEUWEN ML, null LENSEN F, null JOOSTEN E, null LUYTEN FP, and null WESTHOVENS R

Subjects
medicine.medical_specialty, Remitting seronegative symmetrical synovitis with pitting edema, business.industry, Arthritis, General Medicine, medicine.disease, Dermatology, Heart failure, Edema, medicine, Rheumatoid factor, Polyarthritis, medicine.symptom, Age of onset, business, Nephrotic syndrome
Abstract

A 63-year-old man presented with acute symmetrical polysynovitis associated with pitting edema of both the hands and feet. He was seronegative for rheumatoid factor and no radiologically evident erosion was noted in the joints of his hands and feet. Evaluation excluded congestive heart failure, nephrotic syndrome, and hypothyroidism as the cause of edema. Treatment with nonsteroidal anti-inflammatory drugs and low-dose steroids induced complete remission. The clinical manifestations of this patients were consistent with those of a distinctive, although rare, form of arthritis called remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. This syndrome has a good prognosis in elderly patients.

Published
2003

198. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database

Author

Avouac, Jerome, Walker, Ulrich, Tyndall, Alan, Kahan, André, Matucci Cerinic, Marco, Allanore, Yannick, Miniati, I., Müller, A., Iannone, F., Giacomelli, R., Distler, O., Becvar, R., Sierakowsky, S., Kowal Bielecka, O., Coelho, P., Cabane, J., Cutolo, M., Shoenfeld, Y., Rovensky, J., Riemekasten, G., Nicoara, I., Vlachoyiannopoulos, P., Caporali, R., Jiri, S., Inanc, M., Gorska, I. Zimmermann, Carreira, P., Novak, S., Czirjak, L., Ramos, F. Oliveira, Jendro, M., Chizzolini, C., Kucharz, E. J., Richter, J., Cozzi, F., Rozman, B., Mallia, C. M., Gabrielli, A., Farge, D., Kiener, H. P., Schöffel, D., Sticherling, M., Airo, P., Wollheim, F., Martinovic, D., Trotta, F., Hunzelmann, N., Jablonska, S., Reich, K., Bombardieri, S., Siakka, P., Pellerito, R., Bambara, L. M., Morovic Vergles, J., Denton, C., Hinrichs, R., Van Den Hoogen, F., Damjanov, N., Kötter, I., Ortiz, V., Heitmann, S., Krasowska, D., Seidel, M., Hasler, P., Van Laar, J. M., Kaltwasser, J. P., Foeldvari, I., Juan Mas, A., Bajocchi, G., Wislowska, M., Pereira Da Silva, J. A., Jacobsen, S., Worm, M., Graniger, W., Kuhn, A., Stankovic, A., Cossutta, R., Majdan, M., Rajcevska, L. Damjanovska, Tikly, M., Nasonov, E. L., Steinbrink, K., Herrick, A., Müller Ladner, U., Dinc, A., Scorza, R., Sondergaard, K., Indiveri, F., Nielsen, H., Szekanecz, Z., Silver, R. M., Antivalle, M., Espinosa, I. B., García De La Pena Lefebvre, P., Midtvedt, O., Launay, D., Valesini, F., Tuvik, P., Ionescu, R. M., Del Papa, N., Pinto, S., Wigley, F., Mihai, C., Capranu, M. Sinziana, Sunderkötter, C., Jun, J. B., Derk, C., Alhasani, S., Distler, J. H., Ton, E., Soukup, T., Seibold, J., Zeni, S., Nash, P., Mouthon, L., De Keyser, F., Duruöz, M. T., Cantatore, F. P., Strauss, G., Von Mülhen, C. A., Pozzi, M. R., Eyerich, K., Szechinski, J., Keiserman, M., Houssiau, F. A., Rom Ivorra, J. A., Krummel Lorenz, B., Aringer, M., Westhovens, R., Bellisai, F., Mayer, M., Stoeckl, F., Üprus, M., Volpe, A., Buslau, M., Yavuz, S., Granel, B., Feijó, A. Valderílio, Del Galdo, F., Popa, S., Zenone, T., Machado, X. Ricardo, Pileckyte, M., Stebbings, S., Mathieu, A., Tulli, A., Tourinho, T., Souza, R., Acayaba De Toledo, R., Stamp, L., Solanki, K., Veale, D., Neto, J. Francisco Marques, Bagnato, G. F., Loyo, E., Toloza, S., Li, M., Mohamed, W. Ahmed Abdel Atty, Cobankara, V., Olas, J., Salsano, F., Oksel, F., Tanaseanu, C. M., Foti, R., Ancuta, C., Vonk, M., Caramashi, P., Beretta, L., Balbir, A., Shine, B., Chiàla, A., Simic, K. Pasalic, Ghio, M., Stamenkovic, B., Rednic, S., Host, N., Hachulla, E., Furst, D. E., VALENTINI, Gabriele, Avouac, Jerome, Walker, Ulrich, Tyndall, Alan, Kahan, André, Matucci Cerinic, Marco, Allanore, Yannick, Miniati, I., Müller, A., Iannone, F., Giacomelli, R., Distler, O., Becvar, R., Sierakowsky, S., Kowal Bielecka, O., Coelho, P., Cabane, J., Cutolo, M., Shoenfeld, Y., Valentini, Gabriele, Rovensky, J., Riemekasten, G., Nicoara, I., Vlachoyiannopoulos, P., Caporali, R., Jiri, S., Inanc, M., Gorska, I. Zimmermann, Carreira, P., Novak, S., Czirjak, L., Ramos, F. Oliveira, Jendro, M., Chizzolini, C., Kucharz, E. J., Richter, J., Cozzi, F., Rozman, B., Mallia, C. M., Gabrielli, A., Farge, D., Kiener, H. P., Schöffel, D., Sticherling, M., Airo, P., Wollheim, F., Martinovic, D., Trotta, F., Hunzelmann, N., Jablonska, S., Reich, K., Bombardieri, S., Siakka, P., Pellerito, R., Bambara, L. M., Morovic Vergles, J., Denton, C., Hinrichs, R., Van Den Hoogen, F., Damjanov, N., Kötter, I., Ortiz, V., Heitmann, S., Krasowska, D., Seidel, M., Hasler, P., Van Laar, J. M., Kaltwasser, J. P., Foeldvari, I., Juan Mas, A., Bajocchi, G., Wislowska, M., Pereira Da Silva, J. A., Jacobsen, S., Worm, M., Graniger, W., Kuhn, A., Stankovic, A., Cossutta, R., Majdan, M., Rajcevska, L. Damjanovska, Tikly, M., Nasonov, E. L., Steinbrink, K., Herrick, A., Müller Ladner, U., Dinc, A., Scorza, R., Sondergaard, K., Indiveri, F., Nielsen, H., Szekanecz, Z., Silver, R. M., Antivalle, M., Espinosa, I. B., García De La Pena Lefebvre, P., Midtvedt, O., Launay, D., Valesini, F., Tuvik, P., Ionescu, R. M., Del Papa, N., Pinto, S., Wigley, F., Mihai, C., Capranu, M. Sinziana, Sunderkötter, C., Jun, J. B., Derk, C., Alhasani, S., Distler, J. H., Ton, E., Soukup, T., Seibold, J., Zeni, S., Nash, P., Mouthon, L., De Keyser, F., Duruöz, M. T., Cantatore, F. P., Strauss, G., Von Mülhen, C. A., Pozzi, M. R., Eyerich, K., Szechinski, J., Keiserman, M., Houssiau, F. A., Rom Ivorra, J. A., Krummel Lorenz, B., Aringer, M., Westhovens, R., Bellisai, F., Mayer, M., Stoeckl, F., Üprus, M., Volpe, A., Buslau, M., Yavuz, S., Granel, B., Feijó, A. Valderílio, Del Galdo, F., Popa, S., Zenone, T., Machado, X. Ricardo, Pileckyte, M., Stebbings, S., Mathieu, A., Tulli, A., Tourinho, T., Souza, R., Acayaba De Toledo, R., Stamp, L., Solanki, K., Veale, D., Neto, J. Francisco Marque, Bagnato, G. F., Loyo, E., Toloza, S., Li, M., Mohamed, W. Ahmed Abdel Atty, Cobankara, V., Olas, J., Salsano, F., Oksel, F., Tanaseanu, C. M., Foti, R., Ancuta, C., Vonk, M., Caramashi, P., Beretta, L., Balbir, A., Shine, B., Chiàla, A., Simic, K. Pasalic, Ghio, M., Stamenkovic, B., Rednic, S., Host, N., Hachulla, E., Furst, D. E., Chizzolini, Carlo, and Westhovens, Rene

Subjects
Male, Systemic disease, Databases, Factual, Cross-sectional study, Joint Diseases/etiology/pathology/physiopathology, Systemic inflammation, Joint involvement, Scleroderma, systemic sclrosis, systemic inflemmetion, joint involvement, Tendons, Systemic sclerosi, Scleroderma, Localized, 0302 clinical medicine, data base, Immunopathology, joint radiography, Immunology and Allergy, Joints/pathology, scleroderma, 030212 general & internal medicine, nuclear magnetic resonance imaging, Range of Motion, Articular, skin and connective tissue diseases, rheumatic disease, ddc:616, interstitial lung disease, Joint contracture, Clinical Trials as Topic, Synovitis, Inflammation/etiology/pathology/physiopathology, integumentary system, article, Tendons/pathology, Middle Aged, musculoskeletal system, cohort analysis, Connective tissue disease, priority journal, Joint, Synoviti, Systemic sclerosis, Female, medicine.symptom, Joint Diseases, Human, musculoskeletal diseases, Adult, medicine.medical_specialty, hand radiography, Immunology, Scleroderma, Localized/etiology/*pathology, Auto-immunity, transplantation and immunotherapy [N4i 4], 03 medical and health sciences, SYSTEMIC SCLEROSIS, JOINT INVOLVEMENT, SYNOVITIS, JOINT CONTRACTURE, TENDON FRICTION RUB, Tendon friction rub, Rheumatology, Internal medicine, medicine, Humans, Health care ethics [NCEBP 5], Tendon, Aged, 030203 arthritis & rheumatology, Cross-Sectional Studie, Inflammation, skin disease, Scleroderma, Systemic, business.industry, echography, medicine.disease, major clinical study, tenosynovitis, Synovitis/etiology/pathology, clinical feature, body regions, Cross-Sectional Studies, Evaluation of complex medical interventions [NCEBP 2], Scleroderma, Systemic/complications/pathology/physiopathology, Joints, disease duration, business, Joint Disease, disease activity
Abstract

Objective.To determine the prevalence of and independent factors associated with joint involvement in a large population of patients with systemic sclerosis (SSc).Methods.This study was cross-sectional, based on data collected on patients included in the European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) registry. We queried this database to extract data regarding global evaluation of patients with SSc and the presence of any clinical articular involvement: synovitis (tender and swollen joints), tendon friction rubs (rubbing sensation detected as the tendon was moved), and joint contracture (stiffness of the joints that decreased their range of motion). Overall joint involvement was defined by the occurrence of synovitis and/or joint contracture and/or tendon friction rubs.Results.We recruited 7286 patients with SSc; their mean age was 56 ± 14 years, disease duration 10 ± 9 years, and 4210 (58%) had a limited cutaneous disease subset. Frequencies of synovitis, tendon friction rubs, and joint contractures were 16%, 11%, and 31%, respectively. Synovitis, tendon friction rubs, and joint contracture were more prevalent in patients with the diffuse cutaneous subset and were associated together and with severe vascular, muscular, renal, and interstitial lung involvement. Moreover, synovitis had the highest strength of association with elevated acute-phase reactants taken as the dependent variable.Conclusion.Our results highlight the striking level of articular involvement in SSc, as evaluated by systematic examination in a large cohort of patients with SSc. Our data also show that synovitis, joint contracture, and tendon friction rubs are associated with a more severe disease and with systemic inflammation.

Published
2010

200. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis A Randomized Clinical Trial

Author

Laar, J.M. van, Farge, D., Sont, J.K., Naraghi, K., Marjanovic, Z., Larghero, J., Schuerwegh, A.J., Marijt, E.W.A., Vonk, M.C., Schattenberg, A.V., Matucci-Cerinic, M., Voskuyl, A.E., Loosdrecht, A.A. van de, Daikeler, T., Kotter, I., Schmalzing, M., Martin, T., Lioure, B., Weiner, S.M., Kreuter, A., Deligny, C., Durand, J.M., Emery, P., Machold, K.R., Sarrot-Reynauld, F., Warnatz, K., Adoue, D.F.P., Constans, J., Tony, H.P., Papa, N. del, Fassas, A., Himsel, A., Launay, D., Monaco, A. lo, Philippe, P., Quere, I., Rich, E., Westhovens, R., Griffiths, B., Saccardi, R., Hoogen, F.H. van den, Fibbe, W.E., Socie, G., Gratwohl, A., Tyndall, A., EBMT EULAR Scleroderma Study Grp, Rheumatology, Hematology, and CCA - Innovative therapy

Subjects
medicine.medical_specialty, Cyclophosphamide, business.industry, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], medicine.medical_treatment, Hazard ratio, General Medicine, Hematopoietic stem cell transplantation, 3. Good health, Surgery, law.invention, Clinical trial, Transplantation, Autologous stem-cell transplantation, Randomized controlled trial, law, Internal medicine, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], medicine, Clinical endpoint, business, medicine.drug
Abstract

Contains fulltext : 136804.pdf (Publisher’s version ) (Open Access) IMPORTANCE: High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials. OBJECTIVE: To compare efficacy and safety of HSCT vs 12 successive monthly intravenous pulses of cyclophosphamide. DESIGN, SETTING, AND PARTICIPANTS: The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted in 10 countries at 29 centers with access to a European Group for Blood and Marrow Transplantation-registered transplant facility. From March 2001 to October 2009, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until October 31, 2013. INTERVENTIONS: HSCT vs intravenous pulse cyclophosphamide. MAIN OUTCOMES AND MEASURES: The primary end point was event-free survival, defined as time from randomization until the occurrence of death or persistent major organ failure. RESULTS: A total of 156 patients were randomly assigned to receive HSCT (n = 79) or cyclophosphamide (n = 77). During a median follow-up of 5.8 years, 53 events occurred: 22 in the HSCT group (19 deaths and 3 irreversible organ failures) and 31 in the control group (23 deaths and 8 irreversible organ failures). During the first year, there were more events in the HSCT group (13 events [16.5%], including 8 treatment-related deaths) than in the control group (8 events [10.4%], with no treatment-related deaths). At 2 years, 14 events (17.7%) had occurred cumulatively in the HSCT group vs 14 events (18.2%) in the control group; at 4 years, 15 events (19%) had occurred cumulatively in the HSCT group vs 20 events (26%) in the control group. Time-varying hazard ratios (modeled with treatment x time interaction) for event-free survival were 0.35 (95% CI, 0.16-0.74) at 2 years and 0.34 (95% CI, 0.16-0.74) at 4 years. CONCLUSIONS AND RELEVANCE: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment. However, HCST conferred a significant long-term event-free survival benefit. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN54371254.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results